Tinnitus. Tinnitus
Conditions
Interventions
Treatment - Drugs
Placebo
Intervention group: Riluzole 50 mg oral tablet twice daily for three months
Control group: Placebo (similar to the original drug) oral twice daily for three months
Sponsors
Vice-chancellor for research,Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Having a chief complaint of tinnitus Aged between 18-70 Tinnitus More than 3 months
Exclusion criteria
Exclusion criteria: Middle and external ear disease Patients with conductive and mixed hearing loss The presence of the Pulsatile tinnitus type The presence of temporomandibular joint disorders Receiving medications with Systemic effects (in relation to tinnitus) over the past 6 months The presence of tinnitus with a period Less than three months Mild tinnitus (about THI <36) Patients with liver and renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone audiometry. Timepoint: The first day and the 90th day of study. Method of measurement: PTA test.;Tinnitus severity. Timepoint: The first day and the 90th day of study. Method of measurement: THI ( tinnitus handicap inventory) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tinnitus pitch match. Timepoint: The first day and the 90th day of study. Method of measurement: An assessment by an audiologist.;Drug side effect. Timepoint: fourth week. Method of measurement: ask from patient.;Maskability. Timepoint: The first day and the 90th day of study. Method of measurement: An assessment by an audiologist.;Tinnitus loudness match. Timepoint: The first day and the 90th day of study. Method of measurement: An assessment by an audiologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Zahra Mokhtari
Tehran University of Medical Sciences
Outcome results
None listed